Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Omega Diagnostics Group Plc LSE:ODX London Ordinary Share GB00B1VCP282 ORD 4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  3.00 6.45% 49.50 48.00 51.00 52.50 41.00 41.00 3,270,292 12:57:18
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 9.8 1.2 0.8 61.9 89

Omega Diagnostics Share Discussion Threads

Showing 16001 to 16024 of 18325 messages
Chat Pages: Latest  649  648  647  646  645  644  643  642  641  640  639  638  Older
DateSubjectAuthorDiscuss
28/10/2020
07:12
The future is significant revenues !!
amaretto1
27/10/2020
14:48
is now a takeover target, would fit a larger pharmaceutical company or add to a antigen company profile. I saw a few rumours circulating, but would need to see large buys if true.
onehanded
27/10/2020
14:45
Value Target (ODX): 166-177p
valuetracker
27/10/2020
13:38
Tomorrow is a trading update, not the results - it's all about the outlook, progress re COVID tests, progress re CD4, progress in China for Food Intolerance etc. The historic numbers are almost irrelevant.
rivaldo
27/10/2020
12:30
Maybe its better that we are drifting today.The results may surprise us. Hopefully in a good way
upomega
27/10/2020
12:15
Struggling again when others up, hope this isn't a harbinger of tomorrow's presentation (or the much speculated placing).....
control1
27/10/2020
09:46
Barrywhit Dont forget they will also need a cd4200 advanced test together with a test for food allergens.
upomega
27/10/2020
08:49
If the article is correct then it looks like people will need an Antibody test every 4 to 6 months.....not great for the population but good news for Omega and other diagnostic companies...
barrywhit
27/10/2020
08:39
ok so I am thinking more tests required, which is good for odx.
thehitman1
27/10/2020
08:29
https://www.sciencemediacentre.org/expert-reaction-to-a-preprint-from-the-react-2-study-looking-at-prevalence-of-antibody-positivity-to-sars-cov-2/
dmdmdmdm1
27/10/2020
08:28
https://www.google.co.uk/amp/s/www.bbc.co.uk/news/amp/health-54696873Antibodies fall rapidly.any views on above?.
thehitman1
27/10/2020
08:21
I reckon 80p due but then the multibagger follows
ivan danko
27/10/2020
08:16
The times article is good inmo. People have got carried away inmo. Next year us the year. Not now.
upomega
27/10/2020
08:07
The Times article: There are always winners to be found in an economic crisis (Greig Cameron writes). Omega Diagnostics is one. The small Scottish life sciences group dates back to 1987 and was floated on Aim in 2006. Its interests have included kits for testing food allergies and tropical diseases. Until Covid-19, much of the hope around its prospects was in a diagnostic test for HIV indicating when drug treatment is needed. The product, which gives results without the need to use a laboratory, is becoming popular in some African countries, as well as among large non-governmental organisations. Omega’s shares sank to less than 7p in March this year as markets retreated during the initial days of the pandemic, but since then its manufacturing capacity has placed it in a strong position to help in efforts to monitor the spread of the coronavirus. It is part of the UK Rapid Test Consortium and is producing antibody tests for domestic efforts, as well as looking to export to places such as India. At the start of this month Omega said that the consortium had received its first order for a million antibody tests that can show results within 20 minutes using a small drop of blood. It expects to manufacture 175,000 for that first order and to make about 25 per cent of the orders that the consortium receives over the longer term. It says that it will have the capacity to produce 200,000 tests a week by the end of November. Finncap, the house broker, estimates that Omega will receive about £1.50 for every device, with gross margins of 50 per cent. That would mean peak weekly revenue of up to £300,000, with the broker pencilling in £5.7 million of revenue from Covid-19 test production in the year to March 2021. Omega had £9.8 million of revenue in the 12 months to the end of March this year when it made an underlying pre-tax loss of about £400,000. There are other potential growth drivers, too. Its HIV product has passed a procurement milestone for the World Health Organisation and its food allergy kits have been approved by Chinese regulators for laboratory tests. Omega shares hit 107p this month, but were down 3p, or 3 per cent, at 95p today. ADVICE Hold WHY Demand for Covid-19 testing unlikely to tail off soon
jurgenklopp
27/10/2020
07:35
Haggis is awesome. Expansion going very well. What news of who ?
oapknob1
27/10/2020
07:34
upomega, We will find out tomorrow, hopefully they won’t be too bad as it’s all about sales going forward. Fingers crossed..
barrywhit
27/10/2020
07:26
But none of you can offer a view as to what the interims will shed in terms of revenue and how each segment performed. No need to debate that then. Hoesvthe weather up north. What length to keep s lawn in winters haggis vile and shouldnt be eaten on empty stomach
upomega
27/10/2020
07:25
yes antibody testing will now be massively stepped up, a big merger or bid as a lock on to a very big pharmaceutical company is on the cards.
onehanded
27/10/2020
07:18
ODX in the Times Courtesy of Carados on advfn: hxxps://www.thetimes.co.uk/article/perpetual-questions-over-murray-income-trusts-merger-plan-xrlggm72z?shareToken=ff6c1f2220f01d4e39bea56117b000e1
coley15
27/10/2020
07:15
Thanks for the post ant15..
barrywhit
27/10/2020
06:27
Bless you my sons strong sell will suit all you eyh bye gummes.
upomega
27/10/2020
05:41
Imperial College are now of the opinion following substantive investigation That antibodies derived from Infection may only last as long as 80 days before they start to wane and are not detectable. Of course the immune system can "remember" a previous "invasion" by the virus and this should help fight off a secondary bout of the disease but not completely.Furthermore not every individuals' antibody protection will degrade at the same rate. Under the circumstances the need to check antibody levels will be greatly enhanced, as even with a "double dosed vaccine" there is no knowledge or certainty of how long antibodies will remain and hence the protection but it is quite possible that their levels will deplete as above. We know that reinfection by other Corona Viruses is controlled in part by annual "jabs" and it might be that in summer as with these we record a lower rate of infection but see a dramatic increase as we are witnessing now with the onset of winter. We do know that this strain of virus has more deadly side effects than other members of the same class and the need to be vigilant will be sacrosanct. Constant checking of antibody levels or indeed their presence might well become a new norm. In a further "twist" because of the way the antibody levels drop off it is currently thought that only about 5% of the entire population of the UK now has immunity which position will be replicated many times over with the need to assess globally.Undoubtedly and most regrettably for second and third world nations the cost will be prohibitive and they will need massive support from "those that have". Antibody testing will be key even after we have a vaccine!
ant15
26/10/2020
23:01
Britain Britain Britain whete getting there .wow your amazing.
upomega
26/10/2020
19:36
Looks like most lth holders holding below 1.percent have left. Scum buckets.
upomega
Chat Pages: Latest  649  648  647  646  645  644  643  642  641  640  639  638  Older
ADVFN Advertorial
Your Recent History
LSE
ODX
Omega Diag..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201130 14:14:40